These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 37147602)

  • 1. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
    Sun S; Liu C; Duan C; Yu S; Zhang Q; Xu N; Yu B; Wu X; Wang J; Hu X; Yu H
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
    Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
    Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
    Ichihara E; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Cancer Immunol Immunother; 2021 Jan; 70(1):101-106. PubMed ID: 32648165
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Yang D; Feng Y; Lu H; Chen K; Xu J; Li P; Wang T; Xia D; Wu Y
    J Zhejiang Univ Sci B; 2023 Feb; 24(2):143-156. PubMed ID: 36751700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.
    Sun H; Ren P; Chen Y; Lan L; Yan Z; Yang Y; Wang B; Wang C; Li Y; Li L; Zhang Y; Li Y; Wang Z; Pan Z; Jiang Z
    BMC Cancer; 2023 Mar; 23(1):198. PubMed ID: 36864384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
    Front Immunol; 2022; 13():931718. PubMed ID: 35990690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
    Morimoto K; Yamada T; Sawada R; Azuma K; Goto Y; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Tanaka S; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    Cancer Immunol Immunother; 2023 Jun; 72(6):1699-1707. PubMed ID: 36617602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience.
    Bai M; Wang W; Gao X; Wu L; Jin P; Wu H; Yu J; Meng X
    Front Immunol; 2022; 13():832419. PubMed ID: 35296087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
    BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.